Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.

BOCA RATON, Fla., July 27, 2022 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncology and non-oncology conditions, announces the sale of 10 Transdermal Infusion Systems™ to Hair Enhancement Centers (HEC), a growing chain of Texas-based hair loss treatment centers. The systems will be used to non-invasively deliver U.SK Under Skin’s Skin Savers Hair™ Hair Health Serum. U.SK Under Skin is a subsidiary of privately held EMS Pharma, Brazil’s largest pharmaceutical company and itself a subsidiary of Grupo NC, one of Brazil’s largest conglomerates.

Sensus will deliver two systems during the third quarter of 2022 and the remaining systems during the fourth quarter.

“The combination of U.SK Under Skin’s hair health serum and the state-of-the-art Sensus transdermal infusion system ensures that the serum is delivered painlessly and quickly deep into the hair follicle,” Paul commented. Herbman, General Manager. hair enhancement centers. “While HEC leaders have more than 35 years of experience bringing new medical technologies to the global medical market, we rely on a Clinical Advisory Board of leading physicians to evaluate and ultimately recommend technologies that we include in our hair enhancement product offering. I speak for all of us when I say that we are very excited to introduce this option for our customers.”

Andre Freund, General Manager of U.SK Under Skin USA, said, “The Sensus Transdermal Infusion System is an FDA-approved Class II biophysical alternative for infusing high molecular weight modalities into the dermis for medical and aesthetics without needles, pain or downtime. When paired with U.SK Under Skin’s Targeted Skin Saver Ampoules, doctors and aesthetic professionals are able to supercharge the treatments they are already performing, improve results and increase the patient satisfaction in an affordable, easy-to-use treatment. The device passes a painless microcurrent through the skin, allowing Skin Savers to penetrate intercellular water channels without compromising the skin or the solution. TransDermal Infusion can help molecules up to 2 million daltons into the skin for increased bioavailability and a difference in treatment results that patients can see quickly.

“I am impressed with HEC’s progress, growing from two clinics to nine since the start of the year, with expectations for more clinics over the coming months,” said Joe Sardano, President and CEO of Sensus Healthcare. “We are excited to support the future growth of their clinic with our transdermal infusion system to provide U.SK Under Skin’s Hair Health Serum. Renewed hair growth is an important indication because it affects approximately 50 million American men and 30 million American women with male or female pattern baldness, according to the Cleveland Clinic.

“Additionally, our system can painlessly deliver a multitude of drugs for many different medical uses, such as hyperhidrosis, as well as other aesthetic applications,” added Sardano. “Any time you can take the pain out of a procedure, patients and their doctors gain so much from the application,” Sardano continued.

About the Transdermal Infusion System

The transdermal infusion system is FDA cleared for use on any part of the body currently treated with needle injections. This allows various fillers and other injectables to be administered without pain and without downtime for the patient. Faster than traditional iontophoresis, the transdermal infusion system allows for the delivery of medications that otherwise cannot be absorbed, including Botox®, hyaluronic acid, lidocaine, collagen and others typically used in aesthetic procedures.

About Hair Enhancement Centers

Hair Enhancement Centers was founded on the premise that hair loss is a treatable medical condition. HEC believes that its clinical hair growth treatments and doctor-supervised hair transplant procedures are best-in-class solutions and minimally invasive options for treating hair loss in men and women of all ages. Hair Enhancement Centers use only FDA-approved devices and work with respected national and local physicians to deliver breakthrough treatments to their patients. Get Hair™’s new line of medical-grade hair regrowth products are designed to enhance the results of its laser and transdermal infusion treatments.

Hair Enhancement Centers have grown this year from a single location in Southlake, TX a year ago to nine locations, with more to come, serving patients from Dallas/Ft. Worth the metroplex. For more information, please visit www.hec-usa.com

About U.SK Under Skin

U.SK Under Skin is a premium dermocosmetic brand that combines science and efficiency with sophistication and luxury. Founded in 2015, Under Skin brings a new concept to the dermocosmetics market: SCIENCE BEHIND THE BEAUTY. Our products bear the Skin Care High Performance signature and have been developed under the supervision of the most renowned dermatologists, as well as the expertise of the Italian research and development laboratory Monteresearch®, based in Milan. Under Skin combines innovative solutions for all skin types with the latest scientific findings to ensure the most effective products with proven results.

Under Skin’s mission is to bring innovative, high-performance products and technology to dermatologists through international science and design, combined with luxurious sensory experiences to deliver improved health, beauty and lifestyle to our consumers. . Owned by Brazilian company Grupo NC, Under Skin is part of one of the world’s largest pharmaceutical companies, EMS Pharma. For more information, please visit www.underskin.com.

About Sensus Health

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive, and cost-effective treatments for oncology and non-oncology conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of over a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100^™SRT-100+^™ and SRT-100 Vision^™ systems. With its innovative medical device product portfolio, including aesthetic lasers and its needle-free transdermal infusion system^™, Sensus offers breakthrough treatment options to improve the quality of life of patients around the world. For more information, visit www.sensushealthcare.com.

Forward-looking statements

This press release contains statements that are or may be deemed to be “forward-looking statements”. In some cases, these statements can be identified by the use of forward-looking terms such as “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, ” may”, “could”, “could”, “will”, “should”, “approximately”, “potential” or negative or other variations of these terms or comparable terminology, although not all forward-looking statements contain these words.

Forward-looking statements involve risks and uncertainties because they relate to events, developments and circumstances relating to Sensus, our industry and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timeframes. or to a greater or lesser degree than expected. Although we believe we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development industry conditions in which we operate may differ materially from the forward-looking statements contained in this press release due to, among other things, the following factors: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve profitability; our ability to obtain and retain the intellectual property necessary to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third-party payer reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement decreases; regulatory requirements applicable to us and our competitors; our ability to effectively manage our manufacturing processes and costs; risks arising from our international operations; laws, regulations or other government action that affect our products, taxes, international trade regulations or other aspects of our business; the concentration of our customers in the United States and China, including the concentration of sales to a particular customer in the United States; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.

Furthermore, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements we make in this press release speak only as of the date of this statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this release. release, except as may be required by applicable law. You should carefully read our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our activities.

Contact:
LHA Investor Relations
Kim Sutton-Golodetz
212-838-3777
[email protected]

# # #